Navigation Links
The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
Date:8/14/2013

BURLINGTON, Mass., Aug. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Genentech/Chugai's Avastin, although currently not FDA-approved for treatment of ovarian cancer, is prescribed by approximately 70 percent of surveyed oncologists in first-line advanced ovarian cancer. Avastin is most frequently prescribed in first-line advanced ovarian cancer as an add-on agent to doublet platinum-based chemotherapy followed by continued administration of Avastin as a maintenance monotherapy. Approximately half of the surveyed oncologists who prescribe Avastin in first-line advanced ovarian cancer indicate that they encounter reimbursement barriers (such as prior authorization) when prescribing Avastin in this setting.

The U.S. Physician and Payer Forum report entitled Ovarian and Endometrial Cancer: How Will U.S. Prescriber and Payer Attitudes Toward Emerging Antiangiogenics and Other Targeted Anticancer Agents Shape the Treatment Landscape? finds that current treatment of ovarian and endometrial cancers relies heavily on generically available chemotherapies and that carboplatin/paclitaxel is very frequently prescribed in early-stage ovarian cancer, first-line advanced ovarian cancer and in early-stage and advanced endometrial cancer. However, the use of Avastin for treatment of ovarian cancer in all disease settings is common amongst surveyed oncologists and more than 65 percent of surveyed oncologists think that treatment rates with Avastin will increase in the next five years - primarily because they believe Avastin will gain regulatory approval for ovarian cancer. Avastin is rarely used by surveyed oncologists for treatment of endometrial cancer; however, surveyed oncologists believe that angiogenesis inhibitors can play a ro
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BD Completes Sale of Majority of Discovery Labware Unit
2. Allscripts adopts majority voting policy for directors
3. New National Survey Shows Majority of Americans Confident About Choosing Health Coverage
4. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
5. Majority of Springfield Voters Oppose Prescription Only PSE Requirements
6. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
7. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
8. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
9. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
10. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
11. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... SINGAPORE , March 2, 2015 Mount ... center in Singapore to treat ... radiosurgery from Varian Medical Systems (NYSE: VAR ... introduced the new system, which enables advanced forms of ... shaped high-energy radiation beams to attack a tumor from ...
(Date:3/2/2015)... 2015 Valencia Technologies Corporation (" Valencia ... its radically small device for the treatment of high ... this randomized, double-blinded, controlled trial are compelling and provide ... it will succeed in a large U.S. trial for ... Valencia has successfully raised more ...
(Date:3/2/2015)... , March 2, 2015  CytomX, a ... of cancer, today announced the creation of scientific ... and clinicians in the fields of cancer immunotherapy ... new advisory boards will provide guidance to CytomX ... of precision immunotherapies and Probody drug conjugates. The ...
Breaking Medicine Technology:Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 2Mount Elizabeth Novena Hospital to Deliver First TrueBeam STx Radiosurgery Treatments in Singapore 3Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3
... Following recent FDA approvals for prostate cancer treatment ... that the lives of men with advanced prostate cancer ... medication from Johnson & Johnson. The drug, which could reach ... news with the potential to change clinical practice by ...
... SPRING, Md., Oct. 13 The Food and Drug Administration ... a rare type of thigh bone fracture in people ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: ... warning because the rare type of fracture has been ...
Cached Medicine Technology:Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone 2
(Date:3/2/2015)... March 02, 2015 Robins & Morton ... conjunction with Women in Construction Week (March 1-7, sponsored ... NAWIC) and National Women’s History Month, Robins & Morton ... affect the company and the construction industry as a ... to the dozens of roles in between, each woman ...
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), ... health IT to create efficiencies in healthcare information exchange, ... Providers.” The white paper by WEDI’s ICD-10 Testing Subworkgroup ... testing by focusing on primary considerations and steps for ... October 1, 2015 implementation date. Download the white ...
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual ... for people across the country to unite, raise awareness, ... live their best lives. MS Awareness Week is a special ... join the Society’s vision of a world free of MS. ... of the central nervous system, interrupts the flow of information ...
(Date:3/2/2015)... March 02, 2015 Four Seasons Resort Maui ... its 25th anniversary this year, having officially opened its doors ... luxury resort is honoring over 70 employees who started on ... from amongst the approximately 400 original employees. The celebration ... Oceanfront Lawn. , This Four Seasons flagship resort, ...
(Date:3/2/2015)... March 02, 2015 What are the ... physicians request references? When are interviews scheduled, how can ... opportunities?, Both training and practicing physicians who are looking ... questions and more at the PracticeLink Physician Career Advancement ... drop-in Job Fair is from 5:30 to 8:30 p.m. ...
Breaking Medicine News(10 mins):Health News:Robins & Morton Recognizes Women In Construction 2Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... , , Hospitals, ... , PRINCETON, N.J., Aug. 18 Twelve New ... federal government to test an innovative new incentive method that aims ... , The three-year trial program could serve as a ...
... KONG, Aug. 18 IBM (NYSE: IB M ... Life Insurance Company Limited (NYSE: CI ), has implemented ... continuity in the event of disasters or other incidents that could ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/ I BMLOGO ) ...
... 18 EwingCole, a nationally recognized architectural, engineering, interior ... today announced that it will combine its practice with ... with a robust portfolio of healthcare projects. The ... September 1, 2009, will create the Delaware Valley,s largest ...
... , , ... systems for targeted, less-invasive medical treatments, today announced that Massachusetts ... iCT, making it second in the nation and third in ... successfully integrate intra-operative imaging -- from high-field MRI to multi-slice ...
... , ARLINGTON, Va., Aug. 18 "Proposed ... add billions of dollars of un-reimbursed cost to the Medicare ... K.C. McAlpin, executive director of ProEnglish, a national organization that ... the United States. , , The ...
... ELM GROVE, Wis., Aug. 18 Long wait times can ... safety . Many hospitals constantly struggle with moving patients in need of critical ... bed. Compirion Healthcare Soluti o ns is ... Improving Patient Flow - ED to Inpatient , free of charge ...
Cached Medicine News:Health News:Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Medicare Picks N.J. to Test Innovative Incentive System 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 4Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 2Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 3Health News:CIGNA Provides Peace-of-mind for APAC Customers by Ensuring Business Continuity and Resilience with IBM 4Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 2Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 3Health News:Massachusetts General Hospital is Second in Nation to Acquire Both BrainSUITE(R) iMRI and iCT 2Health News:Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units 2Health News:Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units 3
For the quantitative determination of Creatine Kinase in serum....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
For the quantitative determination of total glucose in serum....
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dL (27.8 mmol/L)....
Medicine Products: